Treatment of contact hypersensitivity with urocanic acid.
In order to investigate the effect of cis-urocanic acid (UCA) on a delayed-type hypersensitivity response in humans, a contact hypersensitivity reaction was induced on four test sites on the back of 33 volunteer subjects. The first test site was pretreated with cis-UCA immediately before application of the allergen. The second and third test sites were posttreated on the second and third days of the hypersensitivity response with cis-UCA and a class III corticosteroid, respectively. The fourth test site was used as a positive control. The cutaneous blood flow of the test sites was measured using laser Doppler flowmetry. Pretreatment with cis-UCA reduced the hypersensitivity response significantly. It is possible that cis-UCA could be used in the preventive treatment of contact hypersensitivity responses.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001624:Betamethasone Valerate / Q000627:therapeutic use; D001783:Blood Flow Velocity; D003877:Dermatitis, Contact / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008297:Male; D008875:Middle Aged; D014560:Urocanic Acid / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D001624:Betamethasone Valerate; D014560:Urocanic Acid